The industry sponsored study of 20 children with a variety of underlying primary diagnoses found that zoledronic acid (0.1mg/kg/year) every three months for two years increased bone mineral density (BMD) - particularly in the lumbar spine - and cortical thickness. There was also evidence of vertebral modelling.